glp-1 r retatrutide RETATRUTIDE: A Medication for Diabetes and Weight Loss Retatrutide—A Game Changer in Obesity

Retatrutide has data from thousands of trial participants over relatively short periods

Lilly has the resources to run large, global Phase 3 programs across multiple indications simultaneously

Therapy with GLP-1 and GIP analogues is associated with certain side effects, the risk of developing macro- and micronutrient deficiencies, noticeable cosmetic defects and loss of muscle mass during rapid weight loss, and weight regain after discontinuation of therapy

When P9 binds to ICAM-2, it triggers a signaling cascade that results in GLP-1 secretion

In addition, upregulation of DRP1 contributed to mitochondrial fragmentation and levels of the mitochondrial fission protein DRP1 were increased in a mouse model of type 2 diabetes ( db/db mice) (Huang et al., 2015)